Aurion Biotech secures $120 million financing for cell therapy program
Click Here to Manage Email Alerts
Aurion Biotech has raised $120 million in financing, led by Deerfield Management, according to a press release.
Existing investors included Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision and Visionary Ventures, with participation from Alcon.
The company will use the proceeds to advance its cell therapy program for corneal edema secondary to endothelial dysfunction. Funds will be disbursed based on clinical and operational milestones.
“Our financing speaks volumes about the potential of our cell therapy to transform the lives of millions of people suffering from corneal endothelial dystrophies,” Greg Kunst, CEO of Aurion Biotech, said in the release.
In addition, Andrew ElBardissi, MD, partner at Deerfield Management, and Patrick Lally, partner at Petrichor, will join the company’s board of directors.
Read more about
Click Here to Manage Email Alerts